Cost is King: Why Small Molecule GLP-1 Drugs Are Gaining Popularity in Developing Countries

Introduction

The global demand for GLP-1 (glucagon-like peptide-1) drugs is skyrocketing, driven by their effectiveness in treating type 2 diabetes and, more recently, obesity. GLP-1 receptor agonists like semaglutide and liraglutide have become so popular that sales are projected to reach at least $100 billion by 2030, making them one of the top-selling drug classes worldwidelabiotech.eu. However, these traditional GLP-1 therapies are peptide-based biologics, often administered via injection and carrying hefty price tags. This has sparked a shift toward small-molecule GLP-1 alternatives that can be taken as oral pills. These novel small-molecule GLP-1 agonists promise similar therapeutic benefits with potentially lower production costs and easier distribution, aligning with the needs of cost-sensitive markets.

 

For developing countries, cost and access are king. Many low- and middle-income regions face unique market challenges: healthcare budgets are limited, patients are extremely price-sensitive, and infrastructure for cold storage or injectable delivery may be lacking. In this context, small-molecule GLP-1 drugs – which are cheaper to manufacture, stable at room temperature, and oral – are gaining attention as a more practical solution. This article will explore why developing countries increasingly favor small-molecule GLP-1 medications, how these markets’ needs differ, and how companies like Unibest can help reduce costs and improve access through their extensive pharma networks and expertise.

Understanding GLP-1 and Small Molecule Drugs

What are GLP-1 agonists? GLP-1 receptor agonists are medications that mimic the GLP-1 hormone, enhancing insulin secretion and suppressing glucagon to improve blood sugar control. They also slow gastric emptying and reduce appetite, aiding weight loss – hence their dual use in diabetes and obesity treatmentbhm.scholasticahq.combhm.scholasticahq.com. Traditional GLP-1 drugs (e.g. exenatide, liraglutide, semaglutide) are peptide biologics. They have proven remarkably effective, with trials showing significant HbA1c reductions and even cardiovascular benefits for patientsbhm.scholasticahq.combhm.scholasticahq.com. The downside is that peptides typically require subcutaneous injection, which can deter patients and complicate treatment in resource-poor settings. They also tend to be expensive to produce due to complex biotechnological manufacturing and strict cold-chain distribution requirements.

 

Small molecules vs. biologics: Small-molecule GLP-1 receptor agonists are an emerging class of oral drugs that activate the same GLP-1 pathways but are non-peptidic chemical compounds. The key differences and advantages include:

• Ease of administration: Small molecules can be formulated as pills, eliminating injections and improving patient compliance (no need for syringes or cold storage)bhm.scholasticahq.commdpi.com. This is especially valuable in rural or underserved areas where injection training and refrigeration are challenging.

• Lower manufacturing costs: Producing a small-molecule drug is generally simpler and cheaper than biologic protein drugs. Organic synthesis in chemical reactors can often be scaled at lower cost than cell culture fermentation required for peptidesmdpi.com. For GLP-1 therapy, early evidence suggests these oral compounds could reduce manufacturing and distribution costs compared to injectable peptidesmdpi.com.

• Stability and supply chain: Pills are more stable at room temperature and have a longer shelf-life. They don’t require continuous cold-chain logistics, which offers a huge advantage in resource-limited settingsmdpi.com. Tablets can be shipped and stored more easily, ensuring reliable supply in tropical climates or remote clinics.

• Scalability and future generics: Small molecules lend themselves to generic competition sooner. Once patents expire, many manufacturers (especially in emerging markets) can produce generics, driving prices down dramaticallyschaeffer.usc.edu. By contrast, biosimilars for peptide drugs are harder to develop and may remain expensive. In fact, experts note that oral GLP-1 pills can be scaled up more readily and “would eventually go generic more easily,” increasing affordability over timeschaeffer.usc.edu.

In short, small-molecule GLP-1 drugs maintain the clinical efficacy of GLP-1 agonism – improving glycemic control and inducing weight loss – while offering practical and economic benefits that are particularly relevant outside wealthy markets. The next sections will delve into why these factors make small molecules so appealing to developing countries.

Why Developing Countries Prefer Small Molecule GLP-1 Drugs

Developing countries face a double burden: soaring rates of diabetes and obesity, but limited resources to combat them. Emerging economies in regions like South Asia, the Middle East, Africa, and Latin America are experiencing alarming growth in metabolic diseases due to urbanization, sedentary lifestyles, and dietary changes. For example, India and China now have among the largest diabetic populations globally, and their need for effective treatments is rising rapidlyfuturemarketinsights.comfuturemarketinsights.com. However, these regions are extremely cost-sensitive markets. Patients often pay out-of-pocket, and even middle-class households cannot afford therapies that cost thousands of dollars per year.

 

Cost as a barrier: GLP-1 biologic drugs are notoriously expensive. In the U.S., a year’s therapy with a GLP-1 agonist for obesity can cost $12,000–$16,000pharmacytimes.compmc.ncbi.nlm.nih.gov, far beyond reach for most patients in low-income nations. Even in some countries where prices are lower (~$3,000/year), the cost remains prohibitive for widespread usepmc.ncbi.nlm.nih.gov. A market analysis noted that high cost is the major challenge limiting GLP-1 adoption in lower-income populations, with injectable GLP-1 RAs often priced at hundreds of dollars per month (>$1000/month)towardshealthcare.com. This puts them out of reach for uninsured patients and strains public health budgets, constraining access despite clinical need. Developing regions also tend to have less insurance coverage for novel drugs, meaning patients bear the full costfuturemarketinsights.com.

 

Infrastructure and access issues: Beyond price, practical barriers loom large. Many areas in Africa, Southeast Asia, or Latin America lack the healthcare infrastructure for mass adoption of injectables. Consider that refrigeration and cold chains are required to keep peptide drugs stable; in rural clinics with unreliable electricity, maintaining cold storage for vials is a major hurdle. Additionally, administering injections on a weekly or daily basis requires trained healthcare staff or patient education – feasible in city hospitals but difficult in remote villages. These logistical hurdles have led to poor uptake of biologic GLP-1 therapies in many developing countriesfactmr.com. By contrast, oral small-molecule drugs can be distributed through normal pharmacy channels and taken at home like any other pill, vastly simplifying treatment delivery.

 

Patient preferences and adherence: Cultural and practical preferences also play a role. Patients often prefer pills over injections. In communities where healthcare visits are infrequent, an oral medication that patients can adhere to themselves is more realistic. Small-molecule GLP-1 pills (if affordable) could therefore see much higher patient acceptance and treatment adherence than injectable alternatives, leading to better health outcomes in the long runmdpi.com.

 

All these factors translate into a strong preference for cost-effective oral therapies in the developing world. Small wonder that analysts predict faster growth for GLP-1 markets in emerging economies than in mature Western markets. Asia-Pacific is projected as the fastest-growing GLP-1 market region, driven by countries like China and Indiatowardshealthcare.comfactmr.com. For instance, the expected annual growth rate of the GLP-1 market from 2024 to 2034 is 24.7% in India and 23.1% in China, compared to about 12% in the UKfuturemarketinsights.com

 (a developed market with more saturation). This reflects both the huge unmet need and the anticipated uptake of more accessible options in developing regions. (See Figure 1)

Figure 1: Projected GLP-1 market annual growth rate (CAGR 2024–2034) in selected countries. Emerging economies like India and China show double the growth rate of a developed market (UK), indicating surging demand for GLP-1 therapies in developing regionsfuturemarketinsights.com. Cost-effective oral drugs could help fulfill this demand.

 

Real-world examples: We are already seeing moves in developing markets to embrace small-molecule GLP-1 solutions. For example, Chinese biotech firms are actively working on next-generation GLP-1 drugs; Hansoh Pharma in China even struck a licensing deal with Merck for a new GLP-1 candidate to accelerate its development and commercializationtowardshealthcare.com. In Latin America and the Middle East, health authorities struggling with obesity epidemics are keenly watching oral GLP-1 pills in the pipeline as potential game-changers for mass treatment. Some Gulf countries (with high obesity prevalence) have begun investing in weight-management campaigns and would welcome more affordable oral medications to complement their programsfactmr.com. Meanwhile, patients in places from Southeast Asia to South America often resort to older, cheaper diabetes pills (like metformin or sulfonylureas) because they cannot access pricey injectables. The advent of small-molecule GLP-1 drugs could allow these patients to finally benefit from the superior efficacy of GLP-1 therapy at a fraction of the cost.

 

In summary, developing countries prefer small-molecule GLP-1 drugs because they offer a realistic path to bringing advanced diabetes and obesity treatments to millions more people. Affordability, ease of distribution, and patient-friendly oral dosing align perfectly with what these markets need. Next, we discuss the challenges in making this a reality and how they can be overcome.

Key Challenges and How to Overcome Them

Transitioning to small-molecule GLP-1 therapies is promising, but not without challenges. Both the drugs themselves and the markets in developing countries present hurdles that must be addressed:

• Drug development and manufacturing challenges: While small molecules are cheaper to produce than biologics, they can still be complex. Many oral GLP-1 candidates are novel chemical entities that require specialized chemistry and stringent quality control. Some (like orforglipron’s class) have encountered issues with liver toxicity during trialsmdpi.commdpi.com, underscoring the need for careful R&D. Manufacturing at scale demands access to high-quality APIs (Active Pharmaceutical Ingredients) and intermediates, plus the technical know-how to ensure consistent potency and stability. For companies or regulators in developing countries, ensuring quality is paramount so that these new pills are safe and effective. Another consideration is regulatory approval: new small-molecule drugs will need to clear local regulatory standards, which can be daunting if agencies lack experience with this class.

• Market entry and regulatory barriers: Each country has its own drug approval process and compliance requirements. Navigating the regulatory affairs of multiple emerging markets is challenging, especially for smaller pharma companies. There may be delays in approving novel GLP-1 pills or reluctance until more global data is available. Additionally, issues like patent landscapes and licensing rights come into play if local manufacturers want to produce generics or license-in a drug. Negotiating license deals or setting up joint ventures (NewCos) to bring in new GLP-1 products requires business development expertise and legal acumen.

• Supply chain and distribution reliability: Even oral drugs need a robust supply chain to get from factory to patient. Many developing nations struggle with inconsistent medicine supply, causing stock-outs that interrupt patient therapy. Scaling up production of a new GLP-1 pill and establishing dependable distribution networks in multiple countries can be difficult without strong partnerships. Logistics must be managed to prevent any bottlenecks, and contingency plans should be in place for political or economic disruptions.

• Healthcare provider and patient education: A new class of drug means doctors and patients need to be educated on its use. Habits may be hard to change – some providers might be skeptical of an oral GLP-1’s efficacy compared to injectables, or unaware of its proper dosage and side effects. Patients will need guidance on adhering to the medication (e.g. some oral GLP-1 pills may have specific instructions like taking on an empty stomach). Overcoming these soft challenges is key to successful adoption.

• Extensive supplier networks & cost-effective sourcing: With 20+ years in the pharma industry, Unibest has built a vast network of trusted API and intermediate suppliers in China. We leverage centralized procurement and technical optimizations to cut costs (as outlined in our Cost Control page). By sourcing high-quality raw materials at lower prices, we help partners drastically reduce the manufacturing cost of GLP-1 drugs without compromising quality. For example, our Human Pharma Intermediates Catalog and API Catalog list a wide range of bulk drugs and intermediates that we can supply efficiently. This means even smaller companies or generic manufacturers in developing countries can obtain the ingredients to produce GLP-1 pills at competitive prices – a critical factor in making the final medicine affordable locally.

• Regulatory and export registration support: Unibest’s team has rich experience navigating the regulatory landscapes of various countries. We offer end-to-end support for drug substance (DS) and drug product (DP) registration through our DS/DP Registration service. This includes compiling high-quality dossiers, ensuring compliance with GMP and ICH guidelines, and liaising with regulatory authorities for approvals. By smoothing out the registration process, we accelerate market entry for new GLP-1 products. Our expertise helps overcome regulatory hurdles that might otherwise delay patient access by years.

• Quality control and compliance assurance: Quality is a non-negotiable aspect, especially for a chronic therapy like GLP-1 agonists. Unibest implements rigorous quality control measures (detailed on our Quality Control page) to ensure products meet international standards. We conduct thorough audits of suppliers, employ advanced analytical testing, and enforce compliance with global cGMP. This instills confidence in both regulators and physicians that the small-molecule GLP-1 drugs supplied via Unibest’s network are safe and effective. Our track record in quality is a key reason global partners trust us.

• Technology partnerships and NewCo formation: Where local companies lack specific R&D or formulation know-how, Unibest steps in as a bridge. We facilitate License In/Out and NewCo ventures (see our NewCo & License Out service) by connecting innovators with regional manufacturers. For instance, if a developing-country pharma wants to produce a promising GLP-1 pill but doesn’t have the IP rights or tech, we can arrange a licensing deal with the asset owner, or co-found a new company to develop and commercialize it locally. This kind of matchmaking and project management ensures that breakthroughs in GLP-1 therapy don’t stay confined to rich markets – they can be localized and scaled in cost-sensitive markets quickly and legally.

• Reliable export and logistics management: Unibest has decades of experience in exporting pharmaceuticals globally. We handle all the logistics – from customs documentation to shipping – to guarantee reliable delivery of medicines to our partners. Our familiarity with international trade compliance and our physical presence in China (a major pharma manufacturing hub) allow us to keep supply chains running smoothly. This directly addresses the distribution challenge: we make sure that once a small-molecule GLP-1 drug is produced, it flows efficiently to where it’s needed, with contingency stocks and alternative routes at the ready.

By combining these capabilities, Unibest provides a tailored solution to each major barrier. Manufacturing complexity is tackled by our cost-efficient sourcing and technical expertise; regulatory challenges are eased by our support and licensing models; quality concerns are nullified by our stringent controls; and supply reliability is ensured through our logistics strengths. The result is that pharma companies aiming to introduce small-molecule GLP-1 drugs in developing countries can do so faster, at lower cost, and with greater confidence in success. We essentially act as an extension of your team – an experienced guide through the entire journey of development, registration, and distribution.

Unibest’s Advantage – Reducing Costs and Enhancing Market Access

Unibest Industrial Co., Ltd. distinguishes itself as an ideal partner in the GLP-1 arena by virtue of our holistic approach and proven experience. Here are specific capabilities that give Unibest and our clients a competitive edge in bringing affordable GLP-1 therapies to emerging markets:

 

1. Two Decades of Industry Deep Dive: With over 20 years in the pharmaceutical sector, Unibest has accumulated extensive resources on both ends of the supply chain. On the supply side, we have direct relationships with hundreds of qualified Chinese manufacturers of finished drugs, APIs, and intermediates. On the demand side, we have served clients and partnered with distributors across six continents. This dual knowledge means we understand exactly where to find high-quality, low-cost inputs and how to navigate the export requirements to any target country. Our long history provides assurance that we can handle projects of any scale – whether it’s sourcing a niche intermediate or delivering tons of bulk API – with equal finesse.

 

2. Diverse Product Coverage under One Roof: Unibest’s portfolio covers a wide spectrum of pharmaceutical products and services, making us a one-stop solution. For GLP-1 projects, this is hugely beneficial. We can assist not just with the finished drug, but also upstream and downstream elements. Need a reliable source of exenatide or semaglutide drug substance? Check our API catalog. Looking for key intermediates to synthesize a new small molecule? We likely have them in our network (and listed in our intermediates catalog). Even beyond that, we help with excipients (formulation ingredients), packaging materials, and more. This comprehensive support simplifies your procurement and ensures consistency – all parts of the puzzle are coordinated through one experienced partner.

 

3. Cost Control = Your Competitive Advantage: Cost reduction is where Unibest truly shines. Our entire business model revolves around saving costs while upholding quality – a value proposition perfectly aligned with the “Cost is King” theme. Through strategies like process optimization, bulk purchasing, and even investing in our suppliers for efficiency gains, we achieve remarkable cost savings which we pass on to our clientsunibestpharm.comunibestpharm.com. In practice, this could mean the difference between a GLP-1 pill that costs $1 a dose versus $5 a dose – potentially a game-changer in a developing market. We have a dedicated Cost Saving program that enforces cost cuts at every step, from R&D improvements that increase yield, to green technologies that reduce waste and expenseunibestpharm.comunibestpharm.com. By partnering with Unibest, companies tap into an engine of efficiency that strengthens their pricing power and market competitiveness.

 

4. Quality and Compliance as a Core Strength: While cutting costs, Unibest never cuts corners on quality. Our QA/QC team ensures all products meet stringent international standards (USP, EP, etc.) and that documentation is complete and transparent. We perform on-site audits and implement real-time quality monitoring for every batch produced. This commitment to quality is highlighted on our Quality Control page and is ingrained in our culture. Moreover, we stay up-to-date (even ahead) on regulatory changes worldwide – whether it’s new EMA guidelines for impurities or updated FDA requirements for data integrity. Compliance support is baked into our services. This means that when you work with Unibest, you don’t just get a cheaper product; you get a product that regulators will approve and doctors will trust. Our global partners can attest that Unibest-sourced medications have successfully passed audits and launched in highly regulated markets.

 

5. Success stories and global reach: Unibest has already helped numerous international clients achieve their goals, building a track record that speaks to our capabilities. For instance, as GLP-1 drugs became blockbuster therapies, Unibest was at the forefront assisting a client with a semaglutide generic development package when the opportunity arose for competition (as noted on our LinkedIn, we prepared to support semaglutide production as patents near expiration)ro.linkedin.com. In another case, a Latin American partner leveraged our network to source a critical API and obtained regulatory approval for a diabetes combination product faster than their competitors – thanks to the ready-to-file documentation Unibest provided. We have facilitated license-out deals where Chinese innovators’ GLP-1 analogs were introduced to foreign pharma companies via our NewCo/License Out pipeline. (Our current pipeline includes multiple GLP-1 assets for diabetes, obesity, and NASH, labeled UB080, UB081, etc., which are available for partnership.) Unibest’s involvement often means compressing timelines from years to months and turning prospective opportunities into tangible products on market shelves.

 

In summary, Unibest offers a synergy of cost leadership, quality assurance, and end-to-end support that is hard to match. We reduce the hurdles and amplify the opportunities for companies aiming to bring small-molecule GLP-1 drugs to developing countries. By handling the heavy lifting of supply chain, regulatory, and technical challenges, we let our partners focus on what they do best – whether it’s innovating new formulations or marketing and distribution – confident that the backbone is solid. This advantage not only saves money but also significantly reduces the risk associated with entering new markets or launching new products.

Future Outlook – The Potential of Small Molecule GLP-1 Drugs

The future for small-molecule GLP-1 drugs in developing countries looks exceedingly bright. We are on the cusp of a new era in which these therapies could become widely accessible, mainstream treatments for metabolic diseases across the globe. Several trends and developments point to this potential:

 

Emerging pipeline innovations: The pharmaceutical pipeline for GLP-1 therapies is bursting with activity. As of early 2025, more than 270 clinical trials involving GLP-1 agonists have been registered worldwide, including many exploring oral small-molecule candidates (Figure 2).

This robust R&D pipeline means more competition and more choices. Major pharma players like Eli Lilly, Pfizer, AstraZeneca, and Chinese biotech firms are all advancing proprietary small-molecule GLP-1 compounds

mdpi.com mdpi.com. For example,  orforglipron, Lilly’s oral non-peptide GLP-1 agonist, has successfully completed Phase 3 trials as the first drug of its kind, demonstrating significant HbA1c reductions and weight loss comparable to injectable GLP-1s mdpi.com mdpi.com. This is a groundbreaking validation of the concept – a proof that oral small molecules  can match the efficacy of injectable biologics. Orforglipron is widely expected to receive approvals soon, and analysts predict it could  revolutionize treatment options by expanding access for patients who need GLP-1 therapy futuremarketinsights.com. Other candidates like Pfizer’s danuglipron (though paused due to safety concerns) and newer ones (e.g. Structure Therapeutics’ GSBR-1290, AZD/ACC’s ECC5004) are in advanced trials mdpi.com mdpi.com. In the coming 2–3 years, we anticipate a wave of oral GLP-1 drugs hitting the market, each potentially bringing down costs and catering to different patient segments.  

Market growth and forecasts: All indicators show that developing markets will be a major driver of GLP-1 drug growth in the next decade. Diabetes and obesity rates are climbing fastest in low- and middle-income countries, creating immense demand for effective interventions. At the same time, economic growth and healthcare investments in these regions are improving the ability to pay for medications. Market research projects the global GLP-1 drug market to expand roughly 5-fold from 2024 to 2035 (reaching $300+ billion)factmr.comfactmr.com, with Asia, Latin America, the Middle East, and Africa outpacing Europe/North America in percentage growthfactmr.comfactmr.com. Countries like China and India will contribute a huge share of new demand, as their governments are making novel therapies more accessible through insurance coverage and local manufacturingfuturemarketinsights.comfuturemarketinsights.com. Meanwhile, regions like Africa – currently with lower diabetes treatment rates – represent a vast untapped market that could open up as costs come down. The introduction of affordable oral GLP-1 drugs could be a tipping point that allows these countries to launch nationwide diabetes/obesity programs (much like how cheap generic HIV drugs enabled broad HIV treatment in Africa two decades ago). In Latin America, where middle classes are expanding, we foresee rapid adoption of small-molecule GLP-1 pills in countries such as Brazil and Mexico, especially if local generic production commences to drive prices down.

 

Therapeutic trends and expansions: Small-molecule GLP-1 drugs also hold the promise of broadening indications beyond what current GLP-1 biologics cover. Already, GLP-1 analogs are being explored for NASH (fatty liver disease), polycystic ovary syndrome, and neurodegenerative diseases like Alzheimer’s, due to their beneficial effects on metabolism and inflammationbhm.scholasticahq.combhm.scholasticahq.com. In the future, we might see combination oral pills that incorporate a GLP-1 agonist with other agents (e.g. an SGLT-2 inhibitor or a GIP agonist) to create a single, convenient poly-pill for comprehensive metabolic controlmdpi.commdpi.com. Oral dosage forms make fixed-dose combinations much easier to formulate than mixing injectables. Such innovations could be especially useful in developing countries, where combination pills improve adherence and reduce pill burden for patients managing multiple conditions. Unibest is actively monitoring and participating in these trends – through our R&D collaborations and pipeline, we are positioned to help introduce these next-gen therapies to global markets as they emerge.

 

In light of these developments, Unibest sees itself as a strategic partner for any company aiming to seize the upcoming opportunities in GLP-1 therapeutics. Whether you are:

• A pharmaceutical company in Asia, Africa, or Latin America looking to license in an oral GLP-1 drug for your market,

• A biotech startup with an innovative GLP-1 candidate seeking a license-out or co-development deal to tap global distribution (check our NewCo/License Out services to see how we facilitate such partnerships),

• A generic manufacturer planning ahead for the post-patent landscape (e.g. preparing a generic semaglutide tablet or an orforglipron follow-on),

• Or a healthcare organization wanting a reliable supplier of affordable GLP-1 medications for public health programs,

Unibest is ready to collaborate. We bring to the table our deep expertise, cost advantages, and a commitment to improving global health by making top-quality medicines accessible.

 

The small-molecule GLP-1 revolution aligns perfectly with Unibest’s mission: leveraging our strengths in cost control, quality, and global reach to bridge the gap between pharmaceutical innovation and patients in need. We believe that in the near future, “cost is king” will no longer mean patients in developing countries must settle for older or less effective treatments. Instead, they will have access to the best therapies – like GLP-1 drugs that tackle diabetes and obesity – at prices their healthcare systems can afford. And Unibest will be there to make it happen, one partnership at a time.

Conclusion & Call to Action

In conclusion, small-molecule GLP-1 drugs are poised to become a game-changer for developing countries. These medications check all the boxes for cost-sensitive markets: they are more affordable to produce, easier to distribute (oral pills, no cold chain), and patient-friendly – addressing the key barriers that have made injectable GLP-1 biologics out of reach for many regions. As we’ve discussed, the rising tide of diabetes and obesity in lower-income countries makes it urgent to find cost-effective solutions. With oral GLP-1 therapies, there is a real chance to deliver high-impact treatment on a broad scale – an opportunity to improve millions of lives by preventing complications, reducing healthcare burdens, and even saving lives through better metabolic control.

 

Unibest is uniquely positioned as a catalyst and partner in this movement. By leveraging our supplier networks, quality systems, and experience in global pharma logistics, we help companies dramatically lower their costs and expedite market access for these vital drugs. Our success stories and ongoing projects demonstrate that with the right strategy and support, even complex medications like GLP-1 analogs can be made accessible worldwide without compromising on quality or efficacy.

 

The future of GLP-1 treatment in developing countries is bright: market growth is accelerating, pipelines are rich with new oral agents, and healthcare infrastructures are evolving to integrate these therapies. The “cost is king” mindset is driving innovation towards affordability – and small-molecule GLP-1 drugs are a prime example of this trend. We at Unibest invite pharmaceutical companies, healthcare providers, and distributors from around the world to join forces in this endeavor. Let’s work together to bring these breakthrough treatments to the patients who need them most, at a price point that makes sense.

 

Interested in partnering or learning more? Please contact Unibest or explore our website for more on our services and pipeline. Whether you’re looking to source GLP-1 products, license a new drug, or collaborate on expanding into new markets, we are eager to discuss how Unibest can add value to your objectives.

 

In the world of global health, cost and quality determine outcomes – and with Unibest as your partner, you can confidently achieve both. Together, let’s make “Cost is King” not a limitation, but a winning strategy to improve health outcomes across developing countries.